Next Article in Journal
One-Part Plastic Formable Inorganic Coating Obtain from Alkali-Activated Slag /Starch(CMS) Hybrid Composites
Previous Article in Journal
Modulatory Effect of Chelidonium majus Extract and Its Alkaloids on LPS-Stimulated Cytokine Secretion in Human Neutrophils
Previous Article in Special Issue
Encapsulation of Variabilin in Stearic Acid Solid Lipid Nanoparticles Enhances Its Anticancer Activity in Vitro
Open AccessReview

Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy

University of Torino, Department of Oncology, 10060 Candiolo, Italy
Candiolo Cancer Institute, FPO–IRCCS, 10060 Candiolo, Italy
Author to whom correspondence should be addressed.
Academic Editor: Fabio Pastorino
Molecules 2020, 25(4), 843; (registering DOI)
Received: 31 December 2019 / Revised: 7 February 2020 / Accepted: 11 February 2020 / Published: 14 February 2020
(This article belongs to the Special Issue Recent Advances in Precision Nanomedicine for Cancer)
Phage display is a nanotechnology with limitless potential, first developed in 1985 and still awaiting to reach its peak. Awarded in 2018 with the Nobel Prize for Chemistry, the method allows the isolation of high-affinity ligands for diverse substrates, ranging from recombinant proteins to cells, organs, even whole organisms. Personalized therapeutic approaches, particularly in oncology, depend on the identification of new, unique, and functional targets that phage display, through its various declinations, can certainly provide. A fast-evolving branch in cancer research, immunotherapy is now experiencing a second youth after being overlooked for years; indeed, many reports support the concept of immunotherapy as the only non-surgical cure for cancer, at least in some settings. In this review, we describe literature reports on the application of peptide phage display to cancer immunotherapy. In particular, we discuss three main outcomes of this procedure: (i) phage display-derived peptides that mimic cancer antigens (mimotopes) and (ii) antigen-carrying phage particles, both as prophylactic and/or therapeutic vaccines, and (iii) phage display-derived peptides as small-molecule effectors of immune cell functions. Preclinical studies demonstrate the efficacy and vast potential of these nanosized tools, and their clinical application is on the way.
Keywords: cancer; immunotherapy; phage display; vaccine; peptide; nanocarrier cancer; immunotherapy; phage display; vaccine; peptide; nanocarrier
MDPI and ACS Style

Goracci, M.; Pignochino, Y.; Marchiò, S. Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy. Molecules 2020, 25, 843.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop